Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

first oral therapy

- PMLiVE

Double blow to amyloid drug hopes as Roche, Lilly trial fails

The two investigational candidates were unable to show benefit

Roche Basel Switzerland

Roche builds case for SMA drug risdiplam as FDA verdict nears

Outcome of FDA review due by 24 May

- PMLiVE

Novartis faces criticism over Zolgensma ‘health lottery’

SMA Europe deems access programme 'inappropriate'

- PMLiVE

NICE plans to widen the net for data it uses in guidance

Plans to include electronic health records and real-world evidence

- PMLiVE

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Swiss pharma still managed an 8% increase in pharma sales

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

Roche Basel Switzerland

Roche files Tecentriq/Avastin combo in liver cancer

First treatment in over a decade to improve overall survival

- PMLiVE

EU grants conditional approval to Roche’s lymphoma drug Polivy

Drug demonstrated a 40% complete response rate in trial

- PMLiVE

NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi

Initial guidance says drug is too costly but encourages further data

- PMLiVE

NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

Cost-effectiveness watchdog issues a round of draft and final guidance

Roche Basel Switzerland

Roche and Illumina partner on genomics for cancer diagnostics

Will leverage genomics system to match optimal cancer treatment

- PMLiVE

NICE rejects Akcea’s rare inherited disorder drug Waylivra

Draft guidance deems drug too costly for NHS use

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links